Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration

Clinical trial NCT07554222 · RECRUITING

Trial details

NCT number: NCT07554222
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Active Non-segmental Vitiligo Severe Alopecia Areata

Start date: 2026-04-18
Primary completion: 2027-12-31
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.